Suterafama
4888.TTSE GROWTHPharmaceutical
Filed as STELLA PHARMA CORPORATION (2022-06–2026-06)
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥323m | ¥961m | ¥269m | ¥229m | ¥100m | ¥206m |
| Operating income | −¥749m | −¥90m | −¥760m | −¥807m | −¥742m | −¥681m |
| Ordinary income | −¥778m | −¥138m | −¥760m | −¥776m | −¥764m | −¥656m |
| Total assets | ¥4.5bn | ¥5.4bn | ¥3.8bn | ¥4.3bn | ¥4.7bn | ¥2.0bn |
| Net assets / equity | ¥2.4bn | ¥3.2bn | ¥2.4bn | ¥2.8bn | ¥3.1bn | ¥231m |
| Operating cash flow | −¥335m | ¥140m | −¥877m | −¥828m | −¥1.1bn | −¥773m |
| EPS (basic) | ¥-22.95 | ¥-4.22 | ¥-24.66 | ¥-26.97 | ¥-27.34 | ¥-32.9 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 108 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 66 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 108 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 66 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 107 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 44 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 68 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 42 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 105 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 44 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 68 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 42 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 100 figures · EDINET |
4 more reports are still being processed.